Watch webinars on Evercode™ technology and its applications.
In this webinar, Narges Rezaie, a PhD candidate from the University of California, Irvine, demonstrates how to use topic modeling to identify repeated patterns in single cell data.
During the webinar, Dr. Cong and Yuanhao (Jerry) Qu discussed the advancements made possible by CRISPR Detect. They discuss a new single-cell “perturb and trace” system that combines multiplexed Cas12a perturbations with a machine learning-optimized, single-cell evolvable barcoding system.
In this webinar, Dr. Swarup, demonstrates the protective functions of microglia in reducing CAA, blood-brain barrier dysfunction, and brain calcification. Examination of human AD tissue and iPSC-microglia demonstrates that microglia phagocytose calcium crystals and is impaired by the loss of the AD risk gene, TREM2.
Glioblastoma remains the most common form of brain cancer, exhibiting enormous heterogeneity in the tumor and immune compartments within both the same tumor and between patients. To characterize this heterogeneity within tumor samples and in vitro models, we utilized the Parse Evercode V2 assay to profile whole cells processed from a patient-derived neurosphere line alongside nuclei isolated from a piece of flash-frozen glioblastoma tissue.
This session is part of Parse Biosciences’ 2023 Brain Awareness Month.
With flexible and scalable solutions available, learn why single-cell sequencing studies are no longer out of reach. Watch the webinar recording where our speaker, Dr. Benjamin Ostendorf, Charité-Universitätsmedizin, Berlin, presents the results of his recent single-cell study, published Sep 2022 in the Journal Nature, on the role of APOE in Murine COVID-19 mortality.
In this webinar, you will learn about Evercode TCR for immune profiling and Gene Capture for even greater scalability. You will also learn more about Parse’s foundational technology platform, which enables single cell RNA sequencing with no microfluidics instrument required.
In this webinar, Dr. Katerina Gurova, Roswell Park Cancer Institute, describes how she used scRNA-Seq to examine whether the transition between one epigenetic state into another makes cells vulnerable to oncogene induced transformation.
The gene-regulatory landscape of the brain is highly dynamic in health and disease, coordinating a menagerie of biological processes across distinct cell types. Understanding these regulatory programs requires a holistic experimental and analytical approach. Here, we present a single-cell study of 380,000 nuclei in late-stage Alzheimer’s Disease (AD) using parse biosciences whole transcriptome kit, profiling gene expression in thousands of genes and uncovering vast neuronal and glial heterogeneity in late-stage AD.
Single cell RNA sequencing has become a core tool for researchers to understand biology. As scRNA-seq has become more ubiquitous, many applications demand higher scalability and sensitivity. To meet this need, we developed the Evercode Whole Transcriptome v2 solution, a combinatorial barcoding workflow for scRNA-seq with dramatically improved sensitivity, robustness, and unbiased gene expression.
In this informative webinar recording, Elisabeth Rebboah, UC Irvine, discusses overcoming these obstacles to perform differential RNA isoform expression at single-cell resolution using the split pool combinatorial barcoding protocol from Parse Biosciences along with a combination of short read sequencing to characterize cell types and long read sequencing to reveal full-length isoforms.
The average number of cells profiled in single cell RNA sequencing (scRNA-Seq) experiments has doubled each year since 2015. Yet traditional scRNA-Seq technologies have not scaled well nor do they provide straightforward implementation. Join us for a webinar with Parse Biosciences CTO, Charlie Roco. In it, he describes how straightforward it is to get started and scale with Parse’s combinatorial barcoding technology, Evercode.
Type 2 diabetes (T2D) is a known risk factor for cerebrovascular diseases including Alzheimer’s disease (AD), and vascular dementia (VaD). Yet, our understanding of the mechanisms whereby T2D contributes to neurodegeneration and VaD remains poorly defined. In this study, we utilized the db/db murine model of T2D and single nuclei RNA sequencing to determine the effect of T2D on endothelial cell-specific transcriptomic changes in the hippocampus, an important brain memory center.
Type 2 diabetes (T2D) is a known risk factor for cerebrovascular diseases including Alzheimer’s disease (AD), and vascular dementia (VaD). Yet, our understanding of the mechanisms whereby T2D contributes to neurodegeneration and VaD remains poorly defined. In this present work, we utilized the db/db murine model of T2D and single nuclei RNA sequencing to determine the effect of T2D on endothelial cell-specific transcriptomic changes in the hippocampus, an important brain memory center.
Single Cell RNA Sequencing (scRNA-seq) is helping researchers uncover new insights in ways not possible with traditional bulk RNA sequencing methods. For researchers interested in learning more or just getting started, we’ve developed a series of three educational webinars focused on demystifying scRNA-seq.
In our third and final webinar in the series, we described unique considerations for sequencing and data analysis when doing scRNA-seq experiments.
Single Cell RNA Sequencing (scRNA-seq) is helping researchers uncover new insights in ways not possible with traditional bulk RNA sequencing methods. For researchers interested in learning more or just getting started, we’ve developed a series of three educational webinars focused on demystifying scRNA-seq.
In our second webinar of the series, we described unique considerations for experimental design and sample preparation when doing scRNA-seq projects.
Single Cell RNA Sequencing (scRNA-seq) is helping researchers uncover new insights in ways not possible with traditional bulk RNA sequencing methods. For researchers interested in learning more or just getting started, we’ve developed a series of three educational webinars focused on demystifying scRNA-seq.
In our first webinar of the series, we explored scRNA-seq’s origins and what research questions it can help you answer.
Join us for an informative webinar in which we overview our new single cell BCR and TCR profiling products which enable immune profiling at unprecedented scale. We are also excited to showcase the work of the Reticker-Flynn Lab at Stanford and how they are using single cell immune profiling to understand the process by which tumors evade the immune system and metastasize to invade the body.
The average number of cells profiled in single cell RNA sequencing (scRNA-Seq) experiments has doubled each year since 2015. Yet traditional scRNA-Seq technologies have not scaled well nor do they provide straightforward implementation. Join us for a webinar with Parse Biosciences CTO, Charlie Roco. In it, he describes how straightforward it is to get started and scale with Parse’s combinatorial barcoding technology, Evercode.
Single cell RNA sequencing has become a core tool for researchers to understand biology. As scRNA-seq has become more ubiquitous, many applications demand higher scalability and sensitivity. To meet this need, we developed the Evercode Whole Transcriptome v2 solution, a combinatorial barcoding workflow for scRNA-seq with dramatically improved sensitivity, robustness, and unbiased gene expression.
